The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

(2012) J. Honeychurch et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab

(2011) B. E. Wahlin et al.   CLINICAL CANCER RESEARCH

Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying Cells

(2011) Thomas S. Griffith et al.   IMMUNITY

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

   T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

(2010) M. S. Braza et al.   HAEMATOLOGICA

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE